At the End of Summer: Psilocybin at End of Life
Written by a family member whose parent participated in a psilocybin palliative care trial. What the experience offered, what it didn't, and the change in how they all spent the last months together.
My mother was diagnosed with stage IV pancreatic cancer in March. By July she had enrolled in a palliative care clinical trial — psilocybin for existential distress in terminal illness. She asked me to write this account because, in her words, "I won't be here to tell it, but someone should."
She was 68. A retired nurse. Practically minded in a way that made her initial skepticism about psilocybin legible to everyone who knew her. "I spent my career watching people die. I don't need a drug to tell me what death is." And then: the anxiety that was interfering with her last months. The sleeplessness. The specific dread of suffering in the process.
The trial team was exceptional. Two sessions with a psychiatrist before any medicine. A careful conversation about what she hoped for: not that death would become easy, but that the anxiety about it would stop consuming the time she had left.
She described the session to me afterward in pieces, over several conversations. The early part was visual — colors, patterns, the particular texture of the ceiling becoming interesting in a way she hadn't expected. Around the second hour, something shifted. She said: "It was like I could see that dying was something that happens inside life, not outside it. Not a subtraction. More like — a completion."
She was not cured of dying. She died in September. But the six weeks between the session and her death were qualitatively different from the three months before it. She slept better. She laughed more. The conversations we had were the ones I am most grateful for in my life.
What I want people to know: this research is real, it is rigorous, and it is one of the most humanizing developments in end-of-life care in a generation. If someone you love is dying in fear, there is now a path that has been shown to help.
More Experience Reports
Three years of talk therapy, one psilocybin session, and a fundamentally different relationship with anxiety. A first-timer's account of a licensed Oregon session.
Read →What happens when you underestimate a potent strain. A first-person account of a difficult experience, how the STOP protocol made the difference, and what emerged from the center of it.
Read →A Marine veteran with treatment-resistant PTSD reflects 60 days after participating in a university psilocybin clinical trial. The session didn't cure anything. But the relationship changed.
Read →